State public health regulators have stepped up enforcement against the unauthorized distribution of controlled pharmaceutical formulations across Telangana. The Telangana Standards Authority for Food and Essential Drugs (TG SAFE) issued show-cause notices to 158 medical shops across the state on Wednesday, September 2, 2026.
Special Enforcement Drive Targets Controlled Substances
The regulatory action followed a special enforcement drive targeting the illegal sale of habit-forming medicines without proper medical authorization. According to the TG SAFE bulletin, the targeted formulations included Tramadol, Pregabalin-containing formulations, Nitrazepam, Alprazolam, Tapentadol, Codeine-containing cough syrups, and Zolpidem.
Inspectors identified multiple infractions during the statewide inspections. Violations included selling prescription medicines without a valid prescription from a registered medical practitioner, failure to issue sales bills, non-maintenance or inability to produce sales and purchase records, failure to maintain prescription and Schedule H1 registers, and dispensing prescription medicines in the absence of a registered pharmacist. TG SAFE officials noted that the specific number of medical shops found violating each individual rule has not been detailed, nor has the exact number of absent registered pharmacists been specified.
TG SAFE warned that departmental action, potentially including the suspension or cancellation of drug licenses, will be initiated against violators under the provisions of the Drugs and Cosmetics Act, 1940. Public complaints regarding illegal medicine activities can be reported via the TG SAFE toll-free number 1800 599 6969.
Regulatory Guidance and Historical Precedents
TG SAFE officials advised medical shops to maintain strict vigilance in dispensing prescription medicines and to keep all mandatory records, reiterating that Schedule H, H1, and X medicines must only be sold against valid prescriptions from registered medical practitioners.
This crackdown follows a similar enforcement drive conducted by the Telangana Drugs Control Administration (DCA) between August 14 and August 16, 2026. During that earlier operation, show-cause notices were issued to 43 medical shops for the illegal sale and misuse of weight-loss drugs such as Mounjaro, containing tirzepatide, and Ozempic, containing semaglutide. That preceding drive similarly cited violations involving sales without valid prescriptions and the absence of registered pharmacists.
Downstream Public Health Stakes
The regulatory action aims to enhance public health and safety by curbing the misuse and illegal sale of habit-forming drugs. Medical shop owners found in violation face severe operational consequences, including potential suspension or cancellation of their drug licenses, which could significantly impact their commercial activities. At the same time, consumers will be required to present valid prescriptions for these controlled substances, restricting unregulated access for individuals without legitimate medical needs.
